Cost-Effectiveness Analysis of Treatments for Metastatic Pancreatic Cancer Based on Prodige and MPACT Trials. Issue 3 (May 2016)

• Record Type: Journal Article
• Authors: Zhou, Jing; Zhao, Rongce; Wen, Feng; Zhang, Pengfei; Wu, Yifan; Tang, Ruilei; Chen, Hongdou; Zhang, Jian; Li, Qiu
• Is Part Of: Tumori. Volume 102:Issue 3(2016)
• Page Start: 294
• Page End: 300
• Publication Date: 2016-05
• Subjects: Cost-effectiveness -- FOLFIRINOX -- GEM-N -- Markov model -- Pancreatic cancer; Cancer -- Periodicals; 616.994
• DOI: 10.5301/tj.5000499
• Languages: English
• ISSNs: 0300-8916

Abstract

Purpose: Fluorouracil, leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel (GEM-N) have shown a significant survival benefit for the treatment of metastatic pancreatic cancer. The objective of this study was to assess the cost-effectiveness of FOLFIRINOX versus GEM-N for treating metastatic pancreatic cancer based on the PRODIGE and MPACT trials. Methods: A decision model was performed to compare FOLFIRINOX with GEM-N. Primary base case data were identified from PRODIGE and MPACT trials. Costs were estimated and incremental cost-effectiveness ratio (ICER) was calculated at West China Hospital, Sichuan University, China. Survival benefits were reported in quality-adjusted life-years (QALY). Finally, sensitive analysis was performed by varying potentially modifiable parameters in the model. Results: The base-case analysis showed that FOLFIRINOX cost $37, 203.75 and yielded a survival of 0.67 QALY, and GEM-N cost $32, 080.59 and yielded a survival of 0.51 QALY in the entire treatment. Thus, the ICER of FOLFIRINOX versus GEM-N was $32, 019.75 per QALY gained. Conclusions: The GEM-N regimen was more cost-effective compared with the FOLFIRINOX regimen for the treatment of metastatic pancreatic cancer from a Chinese perspective.